As the RA treatment paradigm shifts from trial-and-error escalation toward precision-driven immunomodulation, Thelansis delivers a definitive 10-year intelligence report covering 31 markets globally. Thelansis has released its comprehensive Moderate to Severe Rheumatoid Arthritis - Market Outlook, Epidemiology, Competitive Landscape, and Market